Pharmaceutical companies have recognized since about 2010 the need for, and benefits of, similar approaches of generating large virtual libraries of easily synthesizable compounds. Examples we can cite here include Pfizer's Global Virtual Library , Boehringer Ingleheim's BI CLAIM , and Eli Lilly's Proximal Lilly Collection (PLC) , the last probably being closest conceptually to SAVI. Still, there are several, and important, difference between these and SAVI, not least the fact that the resulting virtual libraries are proprietary and thus not available to the public.